Growth Metrics

Anika Therapeutics (ANIK) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to -$772,000.

  • Anika Therapeutics' Total Non-Current Liabilities rose 5.58% to -$761,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$761,000, marking a year-over-year increase of 5.58%. This contributed to the annual value of -$772,000 for FY2024, which is 91.09% down from last year.
  • Per Anika Therapeutics' latest filing, its Total Non-Current Liabilities stood at -$772,000 for FY2024, which was down 91.09% from -$404,000 recorded in FY2023.
  • Anika Therapeutics' Total Non-Current Liabilities' 5-year high stood at -$398,000 during FY2022, with a 5-year trough of -$22.3 million in FY2020.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was -$404,000 (2023), whereas its average is -$524,667.
  • In the last 5 years, Anika Therapeutics' Total Non-Current Liabilities plummeted by 6,152.10% in 2020 and then skyrocketed by 94.36% in 2021.
  • Over the past 5 years, Anika Therapeutics' Total Non-Current Liabilities (MRY) stood at -$22.3 million in 2020, then soared by 94.36% to -$1.3 million in 2021, then skyrocketed by 68.36% to -$398,000 in 2022, then decreased by 1.51% to -$404,000 in 2023, then tumbled by 91.09% to -$772,000 in 2024.
  • Its Total Non-Current Liabilities was -$772,000 in FY2024, compared to -$404,000 in FY2023 and -$398,000 in FY2022.